ONCAlert | Upfront Therapy for mRCC

Biomarker-Driven Lung Cancer VIEW MORE >>

The first-in-class AXL inhibitor bemcentinib plus checkpoint inhibitor pembrolizumab induced promising activity in patients with non–small cell lung cancer regardless of PD-L1 status, according to a phase II clinical trial. The data also suggest a greater benefit with the combination in patients who are AXL-positive.
 

Latest JournalAll Journals >>

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.